This compound is primarily utilized in the pharmaceutical industry as an intermediate in the synthesis of fluoroquinolone antibiotics. Its structure is key to developing potent antibacterial agents that target bacterial DNA gyrase and topoisomerase IV, effectively inhibiting bacterial replication. The compound's specific modifications, such as the cyclopropyl group and difluoro substitutions, enhance its binding affinity and spectrum of activity against a wide range of gram-positive and gram-negative bacteria. It is particularly valuable in the development of advanced antibiotics to combat resistant bacterial strains, contributing to the treatment of infections like respiratory, urinary tract, and skin infections.